Latest News
Myqorzo and Redemplo receive regulatory approval in China
15 January 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that China's National Medical Products Administration has approved two Sanofi-licensed medicines: Myqorzo (aficamten) for the treatme...
AVEO Oncology reports first patient dosed in front-line AML combination study of ficlatuzumab
15 January 2026 - US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and venetoclax...
GenomOncology and OHSU Knight Diagnostics Lab partner to enhance clinical trial matching for cancer patients
15 January 2026 - Precision medicine reporting solutions company GenomOncology (GO) announced on Wednesday that it has formed a strategic partnership with Oregon Health & Science University's (OHSU) Knight Diagnostics Lab (KDL) to enhance cl...
Alfasigma SpA collaborates with Innovative Molecules GmbH on potential treatment for HSV encephalitis
15 January 2026 - Italian pharmaceutical company Alfasigma S.p.A. announced on Wednesday that it has formed a strategic partnership with German biotechnology company Innovative Molecules GmbH.Under the agreement, Alfasigma will invest in Innovative M...
Transneural Therapeutics presents new data on TN-001 at 64th Annual Meeting of ACNP
15 January 2026 - Transneural Therapeutics Inc, a neuroscience-focused biotechnology company, on Wednesday reported new data on its lead candidate, TN-001, at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Nassau...